Low insurance reimbursement rates in Taiwan are discouraging the development of innovative pharmaceutical products, according to a study by Fitch Solutions. Because essential healthcare for all residents of the island nation is covered by a single public system, and hospitals negotiate with... Read More
The viability of marketing home-use genetic collection kits to consumers in Asian markets is growing, bolstered by government incentives, increased consumer awareness of their own healthcare needs and improvements in the technology behind the kits themselves. The kits employ state of the... Read More
With China ahead of other major global economic powers in its recovery from the COVID-19 pandemic, its biopharmaceutical industry is surging, driven by its increased capacity for research and development, growing investment in the sector from venture capital firms and a series... Read More
With the COVID-19 pandemic driving growing demand for digital health services, Hong Kong’s government has begun to take some steps to foster telehealth offerings, mobile healthcare apps, and increased use of digital technologies in hospitals and outpatient clinics. The developments include the... Read More
The combination of a relatively low–cost workforce and increasingly reliable quality and ethical standards is turning the Asia-Pacific region into a hub for clinical trials. With pharmaceutical firms under growing pressure to provide innovative new products at reasonable prices, the region is becoming more... Read More
The global medical robotics market is booming, and the Asia Pacific region is expected to experience significant growth over the next 5 years, at a CAGR of 23.32%, according to a report published by Market Data Forecast. The market growth is driven by several factors such... Read More
A host of rehabilitative technology companies are entering the Asian market in force, driven by the needs of the region’s aging population for exercise and rehab equipment to combat immobility, muscular atrophy, and the epidemics of heart disease, hypertension, stroke, osteoarthritis, and... Read More
Three years after China launched a national drug bulk-buying program to negotiate lower prices from drug manufacturers, competitive pressure continues to grow on multinational pharmaceutical companies seeking to compete in the vast country’s market. The results of the fourth round of the... Read More
Cancer is a high priority in China. Incidence rates are rising quickly with lung, colorectal, stomach, liver, and breast being the most numerous. China’s local biotech companies are now focusing on cancer especially R&D in immune-oncology and cell therapies. More China biotechs... Read More
China, Korea, Taiwan, and Japan are rapidly becoming world leaders in cell and gene therapy research and innovation, fueled by significant public and private investment and streamlined regulations that are spurring breakthroughs in the field. All three countries have long been leaders... Read More